Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /dom76025/wp-includes/functions.php on line 6121
Klisyri® (tirbanibulin) has been approved for topical AK treatment - The Dermatology Digest
Subscribe
Search

Klisyri® (tirbanibulin) has been approved for topical AK treatment

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis

— Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp

— Actinic keratosis is the second most common diagnosis made by dermatologists in the United States1

— In one of the largest Phase III clinical study programs2 ever conducted for a topical AK treatment, tirbanibulin demonstrated complete clearance of actinic keratosis lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle

— Klisyri has a demonstrated safety profile with no patient withdrawals due to adverse events, and a convenient 5-day application period which is the shortest of any topical treatment for AK

— This approval represents a key milestone in Almirall’s therapeutic pipeline

Source:

https://www.prnewswire.com/news-releases/almirall-announces-fda-approval-of-klisyri-tirbanibulin-a-new-innovative-topical-treatment-for-actinic-keratosis-301192829.html

Print Friendly, PDF & Email